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12/05 to assess the number of c-DLI administered and the effect
of c-DLI on chimerism. Results: Of 135 allo-BMT, 29 DLI
were administered to 21 pts (median 1 DLI/pt, maximum, 3), 19
of which were c-DLI and 13 of which were for mini-allo-BMT.
A median of 10.5  106 CD3 T cells /kg pt weight (range 5 -
108  106) was administered. No unexpected infusion-related
toxicities or adverse events were encountered. Eight pts were
unevaluable for response, due to full donor chimerism at DLI
(4) or insufﬁcient data after DLI (4). Ten pts received 11 c-DLI
after min-allo-BMT to improve chimerism (4 NHL; 3 CLL; 2
Acute Leukemia; 1 MM). There were 6 responses in T cell
chimerism ( 5% increase) among 5 pts (4 NHL; 1 CLL), 2 to
full donor chimerism (2 NHL). The mean increase in chimerism
after all c-DLIs was 16% (0 - 50) and among responders the
mean increase in T cell chimerism was 24.5% and required a
mean 64 days (range 14 – 130 days). Four of 5 responders were
in CR before c-DLI and remained in CR, while 4 of 5 non-
responders had evidence of disease before and/or after c-DLI
(NS by Chi square). Fifteen pts received 21 c-DLI due to
persistent or recurrent disease (5 AML, 3 CLL, 3 lymphoma, 1
each CML, MM, MDS, Breast). Two pts were not evaluable for
response due to death within 30 days. Three pts had CRs
attributable, at least in part, to DLI (1 each AML, CML, MM).
Conclusions: Prospectively cryopreserved CD3 donor T cells
from mobilized PBSC are frequently employed for DLI after
mini-allo-BMT. Thawed c-DLI are readily available when
needed and are not associated with unexpected infusion toxicity.
C-DLI are frequently effective in improving donor chimerism
post BMT, however a prospective comparison of fresh vs c-DLI
will be required to assess comparative efﬁcacy.
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THYMOGLOBULIN STIMULATES TH2-TYPE ALLORESPONSES AND PRE-
SERVES REGULATORY T CELL (TREG) FUNCTION IN-VITRO
Mahmud, D.1, Chunduri, S.1, Maciejewski, J.J.1, Iqbal, R.1,
Rondelli, D.1 1University of Illinois at Chicago, Chicago, IL.
Thymoglobulin (rabbit anti-thymocyte globulin) is a potent T
cell-depleting agent in-vivo. Nevertheless, its speciﬁc effect on
T cells remains yet to be fully understood. When tested in-vitro
at doses  500 	g/ml thymoglobulin completely depletes T
cells. However, since thymoglobulin level in the serum of
treated patients is consistent with a 100 	g/ml concentration
in-vitro, we tested this dose in culture with puriﬁed T cells
alone, or with allogeneic antigen presenting cells (APCs). Com-
plement and 10% human serum were present in culture media.
In 12-days long kinetics experiments, stimulation with thymo-
globulin on d0, or d0 and d3, or d0, d3 and d6, induced T cell
proliferation, measured by 3H-thymidine uptake, with peaks on
d 4-5. Thymoglobulin also increased T cell responses when
added in primary allogeneic mixed leukocyte culture (MLC). T
cells pretreated with thymoglobulin for 3 d prior to MLC were
hyporesponsive to alloantigen in secondary MLC and did not
show cytotoxic T lymphocyte (CTL) activity, measured by
51Chromium release assay, while proliferated in response to
restimulation with thymoglobulin. Supernatants of MLC with
responder cells pretreated with thymoglobulin for 3 d contained
high levels of IL-13 and IL-5, as opposed to control experiments
with responders pretreated with PHA that showed high levels of
IFN and TNF
. Since after MLC with responders pretreated
with thymoglobulin 90% of T cells were
CD4CD25CD27 we tested the effect of thymoglobulin on
immunomagnetically isolated CD4CD25 (regulatory T
cells, Tregs) or CD4CD25- cells. After 5 d of culture with
thymoglobulin only CD4CD25- cells had proliferated and
both cell subsets expressed CD25, CTLA4, CD62L and GITR.
However, only thymoglobulin-treated CD4CD25 cell ex-
pressed FoxP3 and suppressed T cell alloreactivity when added
to a 3rd party MLC (4227% inhibition). In conclusion, since
we demonstrate that thymoglobulin initially drives T cell allo-
reactivity to Th2-type responses and preserves Tregs immuno-
suppressive activity, these ﬁndings may prompt new studies in
the prevention or treatment of acute GVHD.
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STEM CELL TRANSPLANTATION (SCT) WITH AND WITHOUT CONDI-
TIONING FOR PRIMARY IMMUNE DEFICIENCY (PID) IN CHILDREN: A
SINGLE CENTER 25 YEAR EXPERIENCE
Rosenblatt, H.M.1, Leung, K.1, Myers, G.D.1, Shearer, W.T.1,
Krance, R.C.1 1Baylor College of Medicine, Houston, TX.
Advances in SCT over the past 2 decades have expanded the
spectrum of PID for which this form of curative therapy has
been utilized. Failed, delayed and loss of donor engraftment and
immune function have emerged as signiﬁcant long-term prob-
lems in children with PID. We report the outcomes of condi-
tioned (COND) and non-conditioned (UNCOND) SCT regi-
mens in PID including: several forms of severe combined
immune deﬁciency (SCID), and non-SCID conditions (Wis-
kott-Aldrich syndrome (WAS), chronic granulomatous disease
(CGD), and Omenn syndrome) over the past 25 years. The
majority of transplants in UNCOND SCID and all UNCOND
non-SCID subjects were performed prior to 1999, utilized T
cell depleted bone marrow from related donors, and did not
include GVHD prophylaxis. The majority of transplants in
COND SCID and all COND non-SCID patients were per-
formed in 1999 or later, utilized bone marrow from matched
unrelated and related donors and CD34 selection of apheresed
mobilized stem cells from mismatched related donors. Prophy-
laxis for GVHD was utilized in all recipients of unselected
marrow and in recipients of CD34 selected stem cell products
with 5  104 T cells/kg. A total of 55 patients received 75
transplants with overall survivals of 64% and 82% in UN-
COND and COND patients respectively. Overall survival in 26
UNCOND SCID patients with related donors was 65% vs 80%
in 10 COND SCID patients. Four of 7 UNCOND non-SCID
patients survived vs. 7 of 8 COND non-SCID patients. Among
SCID survivors, 7, 3, and 1 COND patients and 13, 3, and 1
UNCOND patients received 1, 2, and 3 or more transplants
respectively. Among non-SCID survivors all 4 UNCOND and
6 of 7 COND patients received only 1 transplant. Feeding
problems and failure to thrive occurred frequently in SCID
patients prior to transplantation. Signiﬁcant pre transplant pul-
monary disease adversely affected survival in both COND and
UNCOND patients. Fatal post transplant EBV driven lympho-
proliferation was seen in only 1 patient, following an UN-
COND, T cell depleted bone marrow transplant from a hap-
loidentical, EBV sibling. In COND patients, serious post
transplant infections were related to central venous catheters,
and preexisting pulmonary or GI infection. Our experience
suggests that conditioning for SCID and non-SCID children
with severe PID results in excellent survival and may prove to
offer better long term engraftment and immune recovery.
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IMMUNOPHENOTYPIC AND PROTEOMIC CHARACTERIZATION OF CORD
BLOOD (CB) CD56BRIGHT AND CD56DIM NK CELLS: POTENTIAL ROLE OF
CB CD56DIM MEDIATING GVL EFFECT
Shereck, E.1, Satwani, P.1, van de Ven, C.1, Ayello, J.1, Crockett, D.5,
Lim, M.6, Wapner, R.J.2, Day, N.1, Jiang, H.1, Cairo, M.S.1,3,4
1Department of Pediatrics; 2Obstetrics/Gynecology; 3Pathology; 4Medi-
cine, NewYork-Presbyterian, Columbia University, New York, NY;
5Department of Pathology, University of Utah, Salt Lake City, UT;
6Department of Pathology, University of Michigan, Ann Arbor, MI.
NK cells are characterized by absent CD3 and expression of
CD56 and are classiﬁed into CD56dim (90%) that are primarily
cytotoxic, and CD56bright that secrete cytokines (Shankaran et al
Nature 2001). NK subsets carry out their respective functions
based on their repertoire of NK receptors (NKRs) (Moretta et al
Annu Rev Immunol 2001). Despite an immaturity in CB T-cell
immunity, there is a similar leukemic relapse rate following UCBT
vs. UBMT (Cairo et al Blood 1997). Unlike PB NK subsets, there
is little information regarding CB NK subset function and NKR
expression. We compared PB vs. CB NK subset NKR expression
and protein expression. PB and CB cells were positively selected
for CD56 using magnetic beads (Miltenyi) and sorted into CD3
-
/
CD56bright and CD3-/CD56dim and NKR expression measured
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(CD16, CD158a {KIR2DL1} CD158a,h {KIR2DL1 and
KIR2DS1}, CD158b {KIR2DL2}, CD161, NKG2A, NKG2C,
NKG2D, Nkp44, NKp46). 250 	g protein from cell extracts of CB
and PB CD56Dim was labeled with isotope of 1 unit of light (PB)
and heavy (CB) cleavable ICAT reagent and was subjected to
avidin afﬁnity chromatography (Lim et al Lab Invest 2004). The
labeled samples were digested with trypsin and separated by 3-di-
mensional liquid chromatography. Peptides were analyzed with
tandem mass spectrometry (MS) and searched with SEQUEST
TM data base against amino acid sequences in the UniProt protein
database. CD56 selection yielded 89% purity (PB-96%, CB-
89%). There was no statistical difference (mean  SEM) in NKR
expression between the CB CD56dim and PB CD56dim. The PB vs.
CB CD56bright had signiﬁcant increased expression of KIR2DL2
(20.31  2.27 vs. 9.43  0.82, p 0.012) only. The CB CD56dim
vs. bright had increased CD16 expression (85.06  6.75 vs. 40.91 
5.74, p 0.004) only. There were 33 and 37 proteins over and
under expressed by  2 fold between CB and PB CD56dim NK
cells. Differential function of CB overexpressed proteins were 46%
binding, 17% catalytic, 15% signaling, 15% transcription, 3%
enzyme, 2% structural, and 2% transport. In conclusion, PB vs. CB
CD56dim and PB vs. CB CD56bright had similar NKR expression.
The CB vs. PB CD56dim NK cells only had 25% protein expres-
sion differences, mostly in catalytic and binding. We hypothesize
that CB CD56dim in part contribute to the GVL effect post HLA




FIRST LINE SEQUENTIAL THERAPY WITH INTENSIVE CONSOLIDATION
CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ASCT) AFTER REDUCED INTENSITY CONDITION-
ING (RIC) FOR PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
(AML) IN FIRST COMPLETE REMISSION (CR1)
Blaise, D.1, Tabrizi, R.2, Faucher, C.1, Mohty, M.1, Bay, J.O.3,
Boiron, J.M.2, Marit, G.2, Furst, S.1, Charbonnier, A.1, Prebet, T.1,
Chabannon, C.1, Milpied, N.2, Vey, N.1 1Institut Paoli Calmettes,
Marseille, France; 2CHU Bordeaux, Bordeaux, France; 3Centre Jean
Perrin, Clermont Ferrand, France.
We reported that RIC-based ASCT can be used in pts with CR1
AML after intensive consolidation chemotherapy (Blaise, Cancer,
2005; Mohty, Leukemia, 2005). In the present analysis, we inves-
tigated if this control was maintained after longer follow-up. 37 pts
(age: 51 (26-60)) with high risk clinical characteristics (n26; 70%)
(Age  50: 59%; severe comorbidity: 30%)) and/or poor risk
leukemic features (n24; 65%) (Cytogenetics: 35%; failure of ﬁrst
induction course: 27%; secondary leukemia: 11%; High white
blood cell counts: 14%; partial remission: 3%) were included. After
CR1, all pts received a low dose cytarabine chemotherapy followed
one month later by one course of high dose cytarabine (24 g/m2)
and anthracycline (HIDAC). Pts were then scheduled to receive
ASCT after with RIC (ﬂudarabine (180 mg/m2), busulfan (8 mg/
kg), Thymoglobulin (2.5 to 10 mg/kg)) followed with BMT (28%)
or PBSCT (72%). It appeared that this schedule was not associated
prohibitory toxicity. All following pts were, thus, proposed to
receive one month after HIDAC, one course of melphalan (140
mg/m2) (HDMEL) with auto-SCT followed after recovery by the
allo-SCT. Overall, 21 pts received HIDAC only and 16 HIDAC
and HDMEL. Median follow-up is 3 years (16 months-70
months). The cumulative incidence (CI) of grade 2-4 aGVHD was
22% (9-35) (Grade 1: 7; Grade 2: 4; Grade 3-4: 4). The CI of
cGVHD was 65 % (50-80) (Limited: 10; extensive: 14). The CI of
non-relapse death (NRD) was 8% (0-17) (AGVHD: 1; CGVHD:
2). In all, 8 pts relapsed at 5 months (2-19) (CI: 22% (9-35).
Relapse was clearly associated with the absence of cGVHD
(cGVHD: 4% (4-12), no cGVHD 44% (12-76), p.02) and at a
lesser extent with the intensity of consolidation chemotherapy
(HIDAC: 33% (13-53); HIDAC  AUTO; 6% (0-19%), p.06).
26 pts are still alive in CR1 for overall survival and leukemia-free
survival (LFS) probability estimates at 4 years of 67 % (49-81%)
and 68% (50-81%) respectively. When restricting the analysis to
the 33 pts evaluable for cGVHD, cGVHD remained the only
independent risk factor positively inﬂuencing LFS (cGVHD: 83%
(59-74); no cGVHD (56% (27-81), p.03). We conclude that RIC
Allo-SCT preceded by adequate prior intensive chemotherapy
might offer a relatively low NRD while exerting a sustained leu-
kemia control even in high risk pts. The intensity of intensive
chemotherapy needed for optimal treatment will be assessed pro-
spectively.
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THE USE OF ADJUNCTIVE LEUKEMIA SPECIFIC THERAPY TO IMPROVE
OUTCOME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TRANS-
PLANTED USING A REDUCED INTENSITY CONDITIONING (RIC) REGI-
MEN
Craddock, C.F.1, Grifﬁths, M.J.2, Arrazi, J.M.1, Siddique, S.1,
Pallan, L.1, Lennard, A.L.3, Byrne, J.L.4, Olavarria, E.5 1Queen
Elizabeth Hospital, Birmingham, United Kingdom; 2West Midlands
Regional Genetics Laboratory, Birmingham, United Kingdom; 3Royal
Victoria Inﬁrmary, Newcastle upon Tyne, United Kingdom; 4Notting-
ham University Hospitals Trust, Nottingham, United Kingdom; 5Ham-
mersmith Hospital, London, United Kingdom.
Reduced intensity conditioning (RIC) regimens have in-
creased the proportion of patients eligible for allogeneic SCT.
However such regimens are associated with a high risk of early
relapse and this represents the major cause of treatment failure.
Signiﬁcantly the use of donor lymphocyte infusions (DLI) as
salvage therapy in the ﬁrst year post RIC allograft is compli-
cated by a high risk of severe GVHD and consequent morbidity
and mortality. In order to improve the outcome of RIC allo-
grafts there is therefore an urgent requirement for the develop-
ment of strategies which reduce or, at the very least, postpone
the requirement for DLI. We have examined whether the use of
leukemia speciﬁc adjunctive therapy, in the form of the tyrosine
kinase inhibitor Imatinib for the ﬁrst year post transplant, can
be used to improve the outcome of RIC allografts in CML.
Patients with CML in ﬁrst chronic phase and an available sibling
donor underwent allogeneic SCT using ﬂudarabine 125mg/m2,
busulphan 8 mg/kg and alemtuzemab 50 mg. Imatinib was
commenced on day 35 and continued until one year post
transplant. Escalating dose DLI was administered in patients
with evidence of disease relapse after the discontinuation of
Imatinib. 23 patients (median age 49 yrs) were transplanted. All
patients engrafted promptly and demonstrated mixed T cell
chimerism at day90. The day 100 transplant related mortality
was 0%. Two patients developed GVHD (Grades 2 and 3). All
patients commenced Imatinib on day 35, 19 of whom tolerated
continuous treatment until one year post-transplant. All patients
demonstrated a greater than three log reduction in BCR:ABL
transcript numbers in the ﬁrst year post-transplant- 13 achiev-
ing molecular remission. After discontinuation of Imatinib DLI
was instituted in 12 patients as treatment of molecular or cyto-
genetic relapse. Of the 10 patients who have completed a course
of DLI, 9 have achieved durable molecular remissions. 2 pa-
tients developed GVHD in association with DLI. We conclude
that the combination of Imatinib and a reduced intensity allo-
graft is well tolerated in patients with CML and may be an
effective strategy by which the toxicity of allogeneic transplan-
tation can be reduced without compromising its ability to pro-
duce molecular remissions. The use of adjunctive leukaemia
speciﬁc therapy may provide an effective strategy to improve
outcome after RIC allografts in other diseases in which molec-
ularly targeted therapies are available.
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